India’s Anesiva Loses Adlea, Zingo Painkillers From Market
This article was originally published in PharmAsia News
Executive Summary
A Phase III trial failed to support India-based Anesiva's Adlea (capsaicin) painkiller at the same time the firm said it would withdraw another painkiller, Zingo (lidocaine), from the U.S. market. The twin moves, according to an analyst, endanger the company's financial future. The trial showed Adlea failed to meet the main goal of the trial, Anesiva said. It withdrew Zingo because of problems with the shelf life of the drug caused by manufacturing difficulties, Anesiva said. The company said it still seeks to form a partnership with another firm on both drugs. Resurrecting Zingo would take at least a year and millions of dollars, the analyst said. (Click here for more
You may also be interested in...
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.